February 2024 in “Cancers” New treatments targeting androgen receptors show promise for drug-resistant prostate cancer.
10 citations
,
July 2022 in “Journal of Medicinal Chemistry” Adding a second method to PROTACs could improve cancer treatment.
January 2026 in “ACS Applied Bio Materials” A new treatment using nanoliposomes can improve hair regrowth in androgenetic alopecia.
38 citations
,
April 2021 in “JAMA Network Open” Higher variability in systolic blood pressure increases long-term mortality risk in coronary artery disease patients.
3 citations
,
October 2025 in “Cancer” PROTACs offer a new, precise way to treat cancer by breaking down harmful proteins.
October 2025 in “Cermin Dunia Kedokteran” Early detection, prevention, and proper management can reduce TB-IRIS complications and deaths in HIV patients.
49 citations
,
December 2022 in “Pharmacological Reviews” Targeting androgen receptors shows promise for treating triple-negative breast cancer, but more research is needed.
March 2024 in “bioRxiv (Cold Spring Harbor Laboratory)” Minoxidil treatment improves heart defects in a DiGeorge syndrome model.
August 2023 in “Repository of the University of Primorsk (University of Primorska)” A Western diet may increase acne risk, while a Mediterranean diet and certain supplements can help reduce it.
51 citations
,
January 2024 in “Nanoscale” Nano-PROTACs could improve drug targeting and delivery by using nanotechnology.
33 citations
,
November 2019 in “Journal of Controlled Release” Microneedles with enhancer effectively promote hair growth and increase hair density.
23 citations
,
May 2019 in “Expert Opinion on Therapeutic Patents” New androgen receptor modulators show promise for treating diseases like prostate cancer and muscle wasting.
30 citations
,
January 2014 in “Annals of Dermatology” Scalp dermatoscopy helps diagnose and monitor hair loss severity.
68 citations
,
March 2018 in “Biomaterials” Tiny needles with valproic acid can effectively regrow hair.
60 citations
,
January 2023 in “Biomaterials Science” PLGA-based microneedles are promising for safe and effective skin delivery of drugs and vaccines.
11 citations
,
March 2020 in “American Journal of Medical Genetics Part A” A mutation in the EDNRA gene causes Oro-Oto-Cardiac syndrome, affecting face and heart development.
5 citations
,
January 2018 in “PubMed” Biodegradable microneedle patches help topical steroids work better for prurigo nodularis.
44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
9 citations
,
October 2025 in “MedComm” PROTACs offer new ways to treat hard-to-target diseases, with promising drugs for cancer in advanced trials.
6 citations
,
June 2025 in “Nano Biomedicine and Engineering” Smart nano-PROTACs improve cancer treatment by targeting proteins more precisely and reducing side effects.
March 2026 in “Bioconjugate Chemistry” Peptide-based PROTACs show promise in targeting hard-to-treat proteins, especially for cancer therapy.
November 2025 in “Journal of Medicinal Chemistry” Topical PROTACs show promise for treating skin conditions but need better stability and delivery methods.
7 citations
,
January 2023 in “Journal of Hematology & Oncology” Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.
4 citations
,
June 2025 in “MedComm” PROTACs show promise for cancer treatment, but designing them effectively is challenging.
August 2025 in “Therapeutics” Low-dose DMSO may help treat castration-resistant prostate cancer by reducing key cancer cell receptors.
45 citations
,
July 2025 in “Journal of Medicinal Chemistry” The document discusses the submission of a New Drug Application (NDA) to the U.S. FDA for vepdegestrant (ARV-471), a PROTAC protein degrader targeting the estrogen receptor, by Arvinas and Pfizer. This submission is based on positive results from the Phase 3 VERITAC-2 trial and marks a significant milestone as vepdegestrant is anticipated to be the first FDA-approved PROTAC degrader. PROTACs, a novel class of molecules, selectively degrade disease-causing proteins and offer advantages over traditional small molecule inhibitors, such as mitigating off-target effects and overcoming drug resistance. Despite concerns about their large molecular weight and drug-like properties, recent clinical results have been promising. The success of PROTACs has inspired the development of other chimeric molecules for therapeutic applications.
5 citations
,
March 2020 in “Aids Reviews” Hair antiretroviral concentration is affected by hair type, segment position, housing, drug use, sexual behavior, kidney function, and genetics.
24 citations
,
November 2023 in “NEWPORT INTERNATIONAL JOURNAL OF SCIENTIFIC AND EXPERIMENTAL SCIENCES” ART for HIV/AIDS can cause side effects but is crucial for managing the infection.
July 2022 in “Media Dermato Venereologica Indonesiana” The combination of PRP and triamcinolone injections improved hair growth in a man with alopecia areata.
5 citations
,
January 2021 in “iScience” Using a combination of specific cell cycle regulators is better for safely keeping hair root cells alive indefinitely compared to cancer-related methods.